Biosystems and Biomaterials Division
- bbd Expand or Collapse
- About BBD Expand or Collapse
- Core Capabilities Expand or Collapse
- Cell Measurements Expand or Collapse
- Genomic Measurements Expand or Collapse
- Cancer Biomarker Measurements Expand or Collapse
- Genome Editing Measurements
- Microbial Genomic Measurements
- Genome in a Bottle Consortium
- ERCC Control Materials Expand or Collapse
- Advanced Imaging Expand or Collapse
- Biomaterials Expand or Collapse
- Microbial Metrology
- Primary Focus Areas Expand or Collapse
- Measurement Assurance Strategies Expand or Collapse
- Standards and Reference Materials Expand or Collapse
- Collaborations and Partnering
- Interagency Coordination Expand or Collapse
Welcome to the Biosystems and Biomaterials Division
BBD is focused on developing methods that will assure reliability and confidence in the measurements that underpin research and applications in genomic measurements, biomaterials, protein therapeutics and cell therapies, cancer diagnostics, nanoparticle safety, and microbial identification and quantification. We carry out this work through fundamental research in measurement science and the development of reference materials, reference data, and protocols. Click here for an overview video of the Biosystems and Biomaterials Division.
PRIMARY FOCUS AREAS
Advanced therapies are demonstrating promising clinical efficacy and could change the paradigm for treating a wide range of diseases and injuries. Clinical translation of this broad class of new therapeutics requires better defined and characterized products and more robust, reliable, and cost-effective manufacturing processes.
Microbial communities (microbiomes) abound everywhere, forming resilient ecological networks adapted to their environments. Research has connected the behavior of these cooperative communities to both beneficial and problematic outcomes in diverse biological systems including: human health, agricultural productivity, water and food safety, waste remediation, and infrastructure corrosion.
The conventional approach to medicine is rapidly changing to a data-driven strategy in which therapies are individually targeted to a patient based on genome, physiology, environment, or lifestyle. This approach is revolutionizing health care— especially in the treatment of cancer—but its success depends on using data from bioanalytical measurements with potential wide-ranging biases and uncertainties.
Rapid advances in the ability to genetically modify biological organisms have advanced a new engineering discipline, commonly referred to as synthetic biology. This approach seeks to harness the power of living systems for a variety of manufacturing applications, such as advanced therapeutics, sustainable fuels, chemical feedstocks, and advanced materials.
News and Updates
NIST-FDA Workshop Report: Workshop on Standards for Pathogen Detection via Next-Generation Sequencing
Taking Measure Blog Post: Genome in a Bottle: Spelling Out DNA’s ‘Dark’ Sequences
Taking Measure Blog Post: Say Hello to Our Little Friends: Toward Microbial BiotheraPOOtics and Diagnostics
DIVISION CHIEFSheng Lin-Gibson(301) 975-6765DEPUTY CHIEFTara Eskandari(301) 975-3646ADMINISTRATIVE OFFICERKevin Runyon301-975-8428DIVISION OFFICE MANAGERDenise Shaw(301) 975-2629Fax: (301) 330-3447